Pharmaceutical

Coronavirus Disease 2019 (COVID-19) vaccine by China National Biotec Group for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Jan 6, 2025 - 06:00
Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by China National Biotec Group and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.
Read the original article

Tags:

Previous Article

BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

Next Article

Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Dis...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data

STAT+: Pharmalittle: U.K. approves world’s first CRISPR...

Nov 17, 2023

After 2022 interest rate hikes spook investors, pharma M&A to resurge in late 2023

After 2022 interest rate hikes spook investors, pharma ...

May 26, 2023

DB-1310 by Duality Biologics (Shanghai) for Solid Tumor...

Dec 6, 2023